Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032 Jul 1, 2025 09:50AM
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center Nov 15, 2023 04:00AM
Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study May 30, 2023 07:00AM
Annual Changes to the Nasdaq Biotechnology Index Dec 10, 2021 08:00PM
Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics Aug 18, 2021 09:00AM


Jan 19, 2021 07:33AM PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders